FDA Guides the Way to Biosimilars in the US - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Guides the Way to Biosimilars in the US
Has the long-awaited guidance answered all of the industry's questions?


Pharmaceutical Technology
Volume 36, Issue 3, pp. 10

Other items provided in the guidance documents are clear definitions for "protein" and "chemically synthesized polypeptides." These definitions are crucial because the pathway legislation added "protein" to the definition of a biological product for the first time.

Also noted are pediatric assessments, which the draft guidance states are required for a biosimilar product that is not deemed "interchangeable." Pediatric study plans should therefore be part of IND applications.

Overall, FDA is focusing on a step-wise approach for manufacturers and a "totality-of-the-evidence" approach for regulatory assessment for biosimilars. Essentially, the manufacturer needs to look at each step of biosimilarity demonstration, starting with extensive structural and functional characterization of both the proposed product and the reference product, to evaluate "the extent to which there is residual uncertainty about the biosimilarity of the proposed product" and then "identify next steps to try to address that uncertainty." For FDA's part, the agency will be reviewing the "totality of data and information submitted in the application...."

Looking ahead, Sherman noted during the February press briefing that FDA still plans to address naming and tracking standards for biosimilars as well as additional exclusivity issues, which are addressed only briefly in the Q&A draft guidance.

Also on the docket for the future: standards for "interchangeability." Once a product is proved to be biosimilar, a sponsor can work to demonstrate interchangeability, meaning that the biosimilar product produces the same clinical result as the reference product in any given patient, explained Sherman.

Public comments on the draft guidance documents are due to FDA through the Federal Register and will be used to shape the final guidance—hopefully sooner rather than later. The European Union has been ahead of the US in the biosimilar game for years, with approximately 14 approved products under its regional belt. It will be interesting to watch how the global market reacts to FDA's long-anticipated movement forward in this area.

Angie Drakulich is editorial director of Pharmaceutical Technology. Send your thoughts and story ideas to
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here